The core activity of SEITO Biologics is the development of innovative, targeted immunotherapies, in particular selective Treg cell engagers (TREX), aiming to restore balance to the immune system in patients with autoimmune and inflammatory diseases.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Selective Treg cell engagers for the treatment of autoimmune and inflammatory diseases; activate regulatory T cells, promote immune tolerance and correct misdirected immune responses.